Colucci Rocchina, Blandizzi Corrado, Bellini Massimo, Ghisu Narcisa, Tonini Marcello, Del Tacca Mario
Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Via Roma 55, I-56126, Pisa, Italy.
Trends Mol Med. 2008 Jul;14(7):295-304. doi: 10.1016/j.molmed.2008.05.001. Epub 2008 Jun 10.
Serotonin transporter (SERT) mediates the intracellular reuptake of released serotonin, thus regulating its biological functions. Abnormalities in serotonin reuptake can alter enteric serotonergic signalling, leading to sensory, motor and secretory gut dysfunctions, which contribute to the pathophysiology of irritable bowel syndrome (IBS). This relationship has fostered the use of selective serotonin reuptake inhibitors (SSRIs) in the treatment of IBS. Current data on the efficacy of SSRIs in IBS, association of the SERT gene promoter polymorphism 5-HTTLPR with IBS and the expression pattern of SERT in the intestinal mucosa of IBS patients are conflicting. Recent molecular studies have raised critical questions about multiple SERT mRNA transcripts in the human gut, the role of polymorphic SERT promoter in the regulation of enteric SERT expression and the ability of 5-HTTLPR to affect human SERT gene transcription. The present review highlights recent advances in SERT genetics, discusses their implications for potential therapeutic applications of SSRIs in IBS and presents original suggestions for future investigations.
血清素转运体(SERT)介导释放的血清素的细胞内再摄取,从而调节其生物学功能。血清素再摄取异常可改变肠道血清素能信号传导,导致感觉、运动和分泌性肠道功能障碍,这有助于肠易激综合征(IBS)的病理生理学。这种关系促使选择性血清素再摄取抑制剂(SSRI)用于IBS的治疗。目前关于SSRI在IBS中的疗效、SERT基因启动子多态性5-HTTLPR与IBS的关联以及IBS患者肠黏膜中SERT的表达模式的数据相互矛盾。最近的分子研究对人类肠道中多种SERT mRNA转录本、多态性SERT启动子在调节肠道SERT表达中的作用以及5-HTTLPR影响人类SERT基因转录的能力提出了关键问题。本综述重点介绍了SERT遗传学的最新进展,讨论了它们对SSRI在IBS中潜在治疗应用的影响,并提出了未来研究的初步建议。